Get started
Author

Karl Ernst Siegler

Observed names: K SIEGLER, K. E. Siegler, K.-E. Siegler, K.E. Siegler, KARL SIEGLER, Karl E Siegler, Karl E. Siegler, Karl Siegler, Karl E. Siegler
OpenAlex ID: A5006772870
Pharmacokinetic and Pharmacodynamic Profile of New Biosimilar Filgrastim XM02 Equivalent to Marketed Filgrastim Neupogen®
2009 · Heinz Lubenau, Peter Bias, et al. · BioDrugs · 60
What is the “Optimal” follow-up schedule for ICD patients?
2005 · J SENGESBECKER, M KLOSTERMANN, et al. · EP Europace · 56
The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers
2004 · B. Tran‐Mi, H. Storch, et al. · Vox Sanguinis · 53
Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment
2013 · Atef Halabi, Haidar Maatouk, et al. · Clinical Pharmacology in Drug Development · 41
The impact of intensive serial plasmapheresis and iron supplementation on iron metabolism and Hb concentration in menstruating women: a prospective randomized placebo‐controlled double‐blind study
2003 · Anne‐Marie Bier‐Ulrich, Hannelore Haubelt, et al. · Transfusion · 30
PDF
Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab
2002 · Birgit Frilling, Ralf Zahn, et al. · The American Journal of Cardiology · 29
Variability of Holter Electrocardiographic Findings in Patients Fulfilling the Noninvasive MADIT Criteria
2002 · JULIA C. SENGES, RUEDIGER BECKER, et al. · Pacing and Clinical Electrophysiology · 25
Risk factors for symptomatic stone recurrence after transpapillary laser lithotripsy for difficult bile duct stones using a laser with a stone recognition system
2006 · Ralf Jakobs, Dirk Hartmann, et al. · European Journal of Gastroenterology & Hepatology · 17
Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment
2013 · Atef Halabi, Haidar Maatouk, et al. · Clinical Pharmacology in Drug Development · 16
Antibody levels against Chlamydia pneumoniae and outcome of roxithromycin therapy in patients with acute myocardial infarction
2004 · U. Burkhardt*, R. Zahn*, et al. · Zeitschrift für Kardiologie · 7
The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease
2015 · L. Rabinovich‐Guilatt, K. E. Siegler, et al. · British Journal of Clinical Pharmacology · 6
PDF
Effectiveness of the glycoprotein IIb/IIIa antagonist abciximab during percutaneous coronary interventions (PCI) in clinical practice at a single high-volume center
2003 · R. Zahn, B. Fraiture, et al. · Zeitschrift für Kardiologie · 6
Einsatz von Eptifibatid bei der perkutanen koronaren Intervention im klinischen Alltag
2004 · Uwe Zeymer, Ralf Zahn, et al. · Herz · 2
A long way down from an output-window to the bottom of pdf - some shortcuts
2012 · Karl Ernst Siegler
A supplement to the SAS survival guide - nonparametric regression
2012 · Karl Ernst Siegler
1099-91 Treatment and outcome of diabetic patients with stable angina and first angiographic diagnosis of coronary artery disease in Germany: Results of the STAR registry
2004 · Anselm K Gitt, Harm Wienbergen, et al. · Journal of the American College of Cardiology
PDF
Use of glycoprotein IIb/IIIa receptor blockers before and during percutaneous coronary intervention for acute coronary syndromes versus stable angina in consecutive patients in Europe: Results of the international SHAKESPEARE registry
2003 · Anselm K. Gitt, Martin G. Gottwik, et al. · Journal of the American College of Cardiology
PDF
Polymorphisms in the gene for hepatic triglyceride lipase influence plasma lipid levels but are weak predictors for the occurrence and severity of coronary heart disease — the luric study
2001 · M.M. Hoffmann, D. Ahl, et al. · Atherosclerosis Supplements
Polymorphisms in the promotor of apolipoprotein E and their influence on apolipoprotein E plasma levels and cardiovascular risk — the luric study
2001 · M.M. Hoffmann, B.R. Winkelmann, et al. · Atherosclerosis Supplements
Works count: 19
Citation count: 348
H-index: 9
I10-index: 9
Year
Topic
Type